The evolution of single-use technologies (SUTs) is among the most important developments of biomanufacturing. Large stainless-steel containers have long been used for storage and cooling of drug substances. However, there has been a shift toward SUT, which has enhanced manufacturing agility and ﬂexibility. Establishment of single-use systems also has built a solid foundation upon which to improve production of several types of biopharmaceuticals, including mRNA, allogeneic cell therapies, and viral-vectored gene therapies. Especially for emerging modalities, single-use equipment is a logical choice. Manufacturers need to ﬁll, freeze, and ship such therapies quickly. SUTs enable multimodal production, enhance throughput, and expedite changeover procedures. Disposable bioprocess systems also help companies to work ﬂexibly, breaking up conventional batch sizes.
Single Use Support GmbH stands for customer-focused solutions surrounding single-use systems, seeking to improve pharmaceutical ﬂuid management and cold-chain logistics, with the goal of minimizing product loss. Technologies around liquid transfer of biopharmaceuticals continues to evolve through the Austrian-based company’s end-to-end process solutions consisting of sterile consumables such as single-use bioprocess containers, related assemblies, and robust storage and shipping shells for protection of bioprocess solutions. Our product portfolio is constantly growing with SUT platform systems for automated aseptic ﬁlling, controlled and scalable freezing, cold storage, shaking, and shipment of drug substances and products. It is essential to develop ﬂexible end-to-end systems that can be applied with any type of single-use bag or bottle container. The vendor-agnostic approach to ﬂuid management has helped this innovative company succeed.
Single Use Support is well known for being a speedy, agile, and trustworthy partner that provides cutting-edge solutions with short lead times. Proud to have already diminished the incidence of product loss for many customers globally to less than 0.001%, we are paving the way for SUTs to develop further in the coming years.
Fueled by the improved performance of SUTs, we are committed to preventing future bottlenecks for single-use systems. Our slogan, “Pioneering Biopharma,” is manifested in our corporate DNA, and that sentiment will drive us to help advance the pharmaceutical industry.